Icosabutate is under clinical development by NorthSea Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Icosabutate’s likelihood of approval (LoA) and phase transition for Non-Alcoholic Steatohepatitis (NASH) took place on 12 Jan 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Icosabutate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Icosabutate (PRC-4016; PRB-01022) is under development for the treatment of non-alcoholic steatohepatitis (NASH) and insulin resistance. The drug candidate is administered orally. It is a new chemical entity. The drug candidate is a structurally enhanced omega-3 fatty acid derivative with triglyceride (TG) and cholesterol lowering effects. It was also under development for the treatment of hypertriglyceridemia, mixed dyslipidemia and hypercholesterolemia.
NorthSea Therapeutics overview
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Quick View Icosabutate LOA Data
|Highest Development Stage|